Frenelle Private Investor Briefing - NYC
Dear Investors,
Long-acting injectable treatments offer an opportunity to improve access, adherence, and patient experience. Frenelle is applying its proprietary Faros™ drug-delivery technology to one of healthcare’s most significant unmet needs: Opioid Use Disorder.
Join Opus8 and New York Private Equity Forums (NYPEF) for an exclusive investor briefing featuring Frenelle PBC and FRN01, a 30-day subcutaneous buprenorphine injection designed to provide sustained OUD treatment with a more patient-friendly injection experience.
Why Investors Are Taking Notice
$1.2B+ Market — The global long-acting injectable buprenorphine market exceeded $1.2B in 2025, while long-acting treatment remains underpenetrated among patients receiving OUD treatment.
Differentiated Approach — FRN01 is designed to address key barriers associated with existing long-acting products, including injection-site pain, cost, and access.
Promising Preclinical Results — Recent PK and toxicology work demonstrated sustained drug levels over 30 days, low burst release, and a clean toxicology profile.
Experienced Team + Mayo Clinic — Frenelle combines an experienced pharmaceutical development team with Mayo Clinic addiction medicine expertise.
Minimum Check Size: $200K
For investors focused on biotech, specialty pharmaceuticals, addiction medicine, and innovative drug delivery, this is an opportunity to learn more about a differentiated approach to a large and underpenetrated market.
Event Details:
Date: October 5
Time: 5:30 PM EDT
Location: New York City
Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs are subject to review and approval.
Request investor materials by contacting Skylar Rallison at srallison@opus8.com.
Thanks much and all the best,
Tien Wong
CEO
Opus8, Inc.